Cited by 522Preterm Birth and ChorioamnionitisInfant Development and Preterm CareNeonatal Respiratory Health Research

Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data

Open access
Romero, Roberto, Conde-Agudelo, Agustin, Da Fonseca, Eduardo, O’Brien, John M., Cetingoz, Elcin, Creasy, George W., Hassan, Sonia S., Nicolaides, Kypros H.·2018·American Journal of Obstetrics and Gynecology

Abstract

Background The efficacy of vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix has been questioned after publication of the OPPTIMUM study.Objective To determine whether vaginal progesterone prevents preterm birth and improves perinatal outcomes in asymptomatic women with a singleton gestation and a midtrimester sonographic short cervix.Study design We searched MEDLINE, EMBASE, LILACS, and CINAHL (from their inception to September 2017); Cochrane databases; bibliographies; and conference proceedings for randomized controlled trials comparing vaginal progesterone vs placebo/no treatment in women with a singleton gestation and a midtrimester sonographic cervical length ≤25 mm. This was a systematic review and meta-analysis of individual patient data. The primary outcome was preterm birth <33 weeks of gestation. Secondary outcomes included adverse perinatal outcomes and neurodevelopmental and health outcomes at 2 years of age. Individual patient data were analyzed using a 2-stage approach. Pooled relative risks with 95% confidence intervals were calculated. Quality of evidence was assessed using the GRADE methodology.Results Data were available from 974 women (498 allocated to vaginal progesterone, 476 allocated to placebo) with a cervical length ≤25 mm participating in 5 high-quality trials. Vaginal progesterone was associated with a significant reduction in the risk of preterm birth <33 weeks of gestation (relative risk, 0.62; 95% confidence interval, 0.47-0.81; P = .0006; high-quality evidence). Moreover, vaginal progesterone significantly decreased the risk of preterm birth <36, <35, <34, <32, <30, and <28 weeks of gestation; spontaneous preterm birth <33 and <34 weeks of gestation; respiratory distress syndrome; composite neonatal morbidity and mortality; birthweight <1500 and <2500 g; and admission to the neonatal intensive care unit (relative risks from 0.47-0.82; high-quality evidence for all). There were 7 (1.4%) neonatal deaths in the vaginal progesterone group and 15 (3.2%) in the placebo group (relative risk, 0.44; 95% confidence interval, 0.18-1.07; P = .07; low-quality evidence). Maternal adverse events, congenital anomalies, and adverse neurodevelopmental and health outcomes at 2 years of age did not differ between groups.Conclusion Vaginal progesterone decreases the risk of preterm birth and improves perinatal outcomes in singleton gestations with a midtrimester sonographic short cervix, without any demonstrable deleterious effects on childhood neurodevelopment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajog.2017.11.576

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Meta-analyses of randomized controlled trials of women with singleton gestation, no prior spontaneous preterm birth and transvaginal sonographic CL <25mm before 24 weeks have shown that administration of vaginal progesterone significantly decreases the risk of preterm birth and neonatal morbidity.

    “Meta-analyses of randomized controlled trials of women with singleton gestation, no prior spontaneous preterm birth and transvaginal sonographic CL &lt; 25mm before 24weeks have shown that administration of vaginal progesterone significantly decreases the risk of preterm birth and neonatal morbidity 99-101 .”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

3 of the 197 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [4]Institute Of Medicine Committee On Understanding Premature B, Assuring Healthy O The National Academies Collection: Reports funded by National Institutes of Health Behrman RE Butler AS Preterm Birth: Causes, Consequences, and Prevention Washington (DC) National Academies Press (US), National Academy of Sciences 2007 20669423
  2. [53]National Institute for Health and Care Excellence Preterm labor and birth NICE guideline 2015 November 12, 2017 https://www.nice.org.uk/guidance/ng25/evidence/resources/full-guideline-2176838029 37184164
  3. [55]Surveillance report (exceptional review) 2017 - Preterm labor and birth (2015) NICE guidelines NG25 July 3, 2017 http://www.nice.org.uk/guidance/ng25/resources/surveillance-report-exceptional-%20review-2017-preterm-labour-and-birth-2015-nice-guideline-ng25-5642777402053 31869031
  4. [59]Higgins J Altman D Sterne J Chapter 8: assessing risk of bias in included studies Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011

Cited by

Sorted by citations

Authors
Romero, R., Conde-Agudelo, A., Da Fonseca, E., O’Brien, J. M., Cetingoz, E., Creasy, G. W., Hassan, S. S., & Nicolaides, K. H.
Affiliations
  • National Institutes of Health (US)
  • University of Kentucky (US)
  • Population Council (US)
  • Harris Birthright Research Centre for Fetal Medicine (GB)
Corresponding author
Romero, Roberto
Venue
American Journal of Obstetrics and Gynecology
Publisher
Elsevier BV
Published
2018-02
Volume
218
Issue
2
Pages
161-180
ISSN
0002-9378 (ISSN-L)
OpenAlex
W2768850026
Cited by
522
References
197
Citations by year
2026: 42 · 2025: 46 · 2024: 67 · 2023: 53 · 2022: 94 · 2021: 71 · 2020: 69 · 2019: 45 · 2018: 33 · 2016: 1
FWCI
5.33
Type
journal article
Language
en
Open access
Locations
  • American Journal of Obstetrics and Gynecology (acceptedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Perinatology Research Branch
  • Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institutes of Health
  • Department of Health and Human Services
Topics
  • Health Sciences › Medicine › Epidemiology › Preterm Birth and Chorioamnionitis
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Development and Preterm Care
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
Keywords
vaginal progesterone, preterm birth, short cervix, cervical length, singleton pregnancy, perinatal outcomes, respiratory distress syndrome, neonatal morbidity and mortality, neonatal intensive care admission, neurodevelopmental outcomes, preterm birth prevention, birth weight
MeSH terms
Administration, Intravaginal, Uterine Cervical Diseases, Female, Humans, Infant, Newborn, Pregnancy, Pregnancy Outcome, Progestins, Progesterone, Risk, Treatment Outcome, Premature Birth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review